ASCO 2022 | Predicting 177Lu-PSMA-617 in men with prostate cancer with nomograms

Andrei Gafita, MD, University of California, Los Angeles, CA, provides an interview of utilizing nomograms to assess the efficacy of 177Lu-PSMA-617, a radioligand therapy, in patients with metastatic PSMA–positive castration-resistant prostate cancer. PSMA is typically overexpressed in prostate cancer and PSMA positron emission tomography (PET) scans enable the identification of patients who will respond to treatment. The addition of nomograms will enhance the process of patient selection. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.